# LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

> **NCT01856478** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 340 (actual)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT01856478
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-07
- **Primary completion:** 2018-08-22
- **Final completion:** 2024-10-02
- **Target enrollment:** 340 (ACTUAL)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01856478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01856478, "LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy". Retrieved via AI Analytics 2026-05-19 from https://api.ai-analytics.org/clinical/NCT01856478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*